{
  "catalogId": "35ae22f7-e802-45fe-8b30-13dccbb26584",
  "name": "ILARIS 150 MG/ML SOLUTION FOR INJECTION",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "161 35 35349 00",
  "treatmentDescriptions": "►Periodic Fever SyndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-Associated Periodic Syndromes (CAPS)Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including:•\tMuckle-Wells syndrome (MWS),•\tNeonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),•\tSevere forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.►Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).►Hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD).►Familial Mediterranean Fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF) in patients in whom colchicine is contraindicated, is not tolerated, or does not provide an adequate response despite the highest tolerable dose of colchicine.Ilaris can be given as monotherapy or in combination with colchicine.Ilaris is also indicated for the treatment of:►Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.►Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate",
  "termsOfIssue": "Prescription required",
  "form": "solution for injection",
  "route": "s.c",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "CANAKINUMAB/",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L04AC08",
      "name": "CANAKINUMAB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "ILARIS 150 MG/ML SOLUTION FOR INJECTION 1 VIAL",
      "manufacturer": {
        "name": "נוברטיס פארמה",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 1.0,
        "unit": "units"
      },
      "packagingDescription": "VIAL GLASS TYPE I",
      "shelfLife": "36",
      "storageConditions": "",
      "codes": {
        "moh": "8415",
        "yarpa": "38474",
        "pharmasoft": "10461",
        "barcode": "7290016369526"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": 43978.73663,
        "retailMargin": 10.0,
        "maxRetailPrice": 48376.61029,
        "maxPriceWithVAT": 57084.3976
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T22:09:12.003338"
  }
}